The popular COVID treatment, Paxlovid, does not significantly lower the risk of "long COVID" for people who are vaccinated.


3769151

abc 7 Chicago

Chicago

Cook County

Illinois

United States

Paxlovid does not lower risk of long-term COVID-19 symptoms, UCSF study shows

The popular COVID treatment, Paxlovid, does not significantly lower the risk of "long COVID" for people who are vaccinated, according to a UCSF study.

Media Bias/Fact Check

abc 6 Philadelphia

The Walt Disney Company

Philadelphia

Philadelphia County

Pennsylvania

In a new study from UCSF, researchers found that patients who took Paxlovid and those who did not had similar outcomes when it came to long COVID symptoms.

abc 13 Houston

Houston

Harris County

Texas

Ad Fontes Media

abc 7 LA

Los Angeles

Los Angeles County

California

abc 7 NY

New York

abc11 Raleigh

Raleigh

Wake County

North Carolina

US researchers have investigated how effective Paxlovid was during the pandemic — and whether it reduced the risk of developing long Covid as a result.

US-Forscher haben untersucht, wie wirksam Paxlovid während der Pandemie war - und ob es in Folge das Risiko reduziert hat, Long Covid zu entwickeln.

Studie: Kann Paxlovid das Risiko für Long Covid reduzieren?

Kurier

Funke Mediengruppe

Study: Can Paxlovid reduce the risk of long Covid?

A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection.

Paxlovid does not lower risk of long-term COVID-19 symptoms, UCSF study shows

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics